PMID- 22846866
OWN - NLM
STAT- MEDLINE
DCOM- 20121004
LR  - 20220318
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 39
IP  - 4
DP  - 2012 Aug
TI  - Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: 
      current status and future perspectives.
PG  - 493-502
LID - 10.1053/j.seminoncol.2012.05.014 [doi]
AB  - Improving the overall survival for patients with advanced hepatocellular 
      carcinoma (HCC) requires development of effective systemic therapy. Despite the 
      successful approval and extensive application of sorafenib, the prognosis for 
      patients with advanced HCC remains poor and the benefits with sorafenib are 
      modest. In the past few years, there have been renewed and continued interests 
      and active research in developing other molecularly targeted agents in HCC. While 
      the initial efforts are focusing on anti-angiogenic therapy, other agents 
      targeting the epidermal growth factor-receptor, mammalian target of rapamycin 
      (mTOR), hepatocyte growth factor/c-Met among others have entered HCC clinical 
      trials. Combining different molecularly targeted agents or combining targeted 
      agents with chemotherapy represent other strategies under investigation. This 
      review will attempt to summarize the current status of other molecularly targeted 
      agents or regimens beyond sorafenib under development in advanced HCC and the 
      future perspectives.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Zhu, Andrew X
AU  - Zhu AX
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 
      02114, USA. azhu@partners.org
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Carcinoma, Hepatocellular/blood supply/*drug therapy
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Histone Deacetylase Inhibitors/therapeutic use
MH  - Humans
MH  - Liver Neoplasms/blood supply/*drug therapy
MH  - Proto-Oncogene Proteins c-met/antagonists & inhibitors
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
EDAT- 2012/08/01 06:00
MHDA- 2012/10/05 06:00
CRDT- 2012/08/01 06:00
PHST- 2012/08/01 06:00 [entrez]
PHST- 2012/08/01 06:00 [pubmed]
PHST- 2012/10/05 06:00 [medline]
AID - S0093-7754(12)00117-0 [pii]
AID - 10.1053/j.seminoncol.2012.05.014 [doi]
PST - ppublish
SO  - Semin Oncol. 2012 Aug;39(4):493-502. doi: 10.1053/j.seminoncol.2012.05.014.